Related Experiment Video
Updated: Apr 22, 2026

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
Published on: June 16, 2018
In vitro tolerability of soluble silicic acid and tetraethyl orthosilicate in ocular epithelial cells
Aleksandra Poluianova1,2, Alexandra Robciuc3, Ville Pollari4
1Helsinki Eye Lab, University of Helsinki, Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland. aleksandra.d.poluianova@gmail.com.
Abstract:
Biodegradable silica microparticles (SiMPs) are a promising carrier matrix for controlled ocular drug delivery. In tissues, SiMPs degrade into silicic acid (SiA), a soluble inorganic weak acid. This study evaluated the in vitro toxicity and tolerability of SiA and SiMPs' precursor, tetraethyl orthosilicate (TEOS), in human corneal epithelial cells (HCE-2) and retinal pigment epithelial cells (ARPE-19). Cells were exposed to serial dilutions of SiA and TEOS. Cell viability was assessed after 24, 48, and 72 h using the alamarBlue assay, while membrane integrity was analyzed through LDH release. To evaluate cellular stress from SiA and TEOS, levels of pro-inflammatory, apoptosis, and heat shock stress response markers were measured. Neither viability assay revealed significant differences in survival rates between the control group and 30 µg/mL SiA in ARPE-19 and HCE-2 cells at all time points. ARPE-19 viability decreased with low SiA concentrations, but this was not supported by LDH release or caspase-3 activation. Inflammatory markers IL-6, IL-8, and MCP-1 secretion or heat shock protein 70 expression levels were not changed in either cell line in response to SiA. Conversely, TEOS reduced cell viability at high concentrations (0.6-2.4 mg/mL) and affected the cytokine response in both cell lines. Our results indicate that both cell lines can tolerate SiA concentrations up to 30 µg/mL. In contrast, TEOS showed toxicity at concentrations above 0.6 mg/mL, which greatly exceeds expected levels in the SiMP formulation. These findings support the use of SiMPs as drug delivery vehicles in ophthalmic formulations.

